Anika Therapeutics | ANIK - Assets


Anika Therapeutics reported $183.47M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Abbott USD 110.43B 23.72B Mar/2026
Agenus USD 172.69M 13.76M Jun/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Halozyme Therapeutics USD 2.58B 95.31M Jun/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Insmed USD 2.1B 26.7M Jun/2026
Integra LifeSciences USD 3.56B 14.24M Jun/2026
Intrexon USD 73.16M 77.88M Jun/2024
J&J USD 201.06B 167M Jun/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Ligand Pharmaceuticals USD 2.19B 653.77M Jun/2026
MacroGenics USD 345.41M 127.54M Jun/2026
Merit Medical Systems USD 2.86B 144.34M Jun/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 129.06B 1.04B Jun/2026
Smith & Nephew USD 11.01B 321M Jun/2026
Stryker USD 47.93B 1.64B Jun/2026
Veracyte USD 1.49B 49.97M Jun/2026
Xencor USD 724.96M 11.89M Jun/2026
Zimmer Biomet Holdings USD 22.8B 76.2M Jun/2026